Synthetic Biologics (SYN) Stock Price, News & Analysis

Company Overview

Synthetic Biologics, Inc. is a clinical‐stage biopharmaceutical company headquartered in Rockville, Maryland, focused on developing novel therapies to prevent and treat serious bacterial infections by preserving the integrity of the gut microbiome. The company’s research platform leverages enzyme and microbiome modulation technologies to counteract the unintended consequences of antibiotic therapies, aiming to reduce the incidence of Clostridioides difficile infection and other antibiotic‐associated complications.

The company’s lead product candidate, ribaxamase (SYN-004), is an orally administered beta‐lactamase enzyme designed to degrade certain intravenous beta‐lactam antibiotics in the gastrointestinal tract, thereby protecting the gut from antibiotic‐induced dysbiosis. Ribaxamase has been evaluated in multiple clinical trials, including studies in patients undergoing treatment for serious infections such as pneumonia. Synthetic Biologics has also been advancing additional pipeline programs that explore microbiome‐based approaches for gastrointestinal and metabolic disorders.

Synthetic Biologics collaborates with pharmaceutical partners to facilitate global development and commercialization, having secured agreements to support late‐stage studies and future market access. The company is led by President and Chief Executive Officer William H. Martin, under the guidance of an experienced board with deep expertise in biopharmaceutical research and development. Synthetic Biologics is committed to innovating solutions that address critical unmet needs in infectious disease and gastrointestinal health.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 57,700 shs
• Average Volume: 197,338 shs
• Market Capitalization: $16.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SYN Stock Analysis - Frequently Asked Questions

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10.

When did Synthetic Biologics' stock split?

Synthetic Biologics's stock reverse split before market open on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Synthetic Biologics?

Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Meta Platforms (META).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 9/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:SYN
• CIK: 894158
• Web: www.syntheticbiologics.com
• Phone: (301) 417-4364
• Fax: 301-417-4367
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.14%
• Return on Assets: -22.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.14
• Quick Ratio: 4.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,844,000
• Free Float: 15,503,000
• Market Cap: $16.16 million
• Optionable: Not Optionable
• Beta: 1.38